How long until I see results from TB-500?

Acute effects from TB-500 appear within the first week for downstream physiological adaptation. healthspan and biological-age endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Is TB-500 safe during pregnancy or breastfeeding?

TB-500, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What route should I use for TB-500?

TB-500 is delivered by subq/im. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

What does TB-500 stack well with?

For longevity / hallmarks of aging protocols, TB-500 pairs with compounds on complementary pathways: Epithalon, Thymalin, NAD+. These pairings are selected because they engage independent receptor systems from TB-500's primary mechanism (Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool), producing additive or synergistic effects rather than receptor competition.

What should I look for in TB-500 sourcing and quality?

Acceptable TB-500 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 888-1717 Da (depending on form), endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How does TB-500's half-life affect dosing?

TB-500 has a plasma half-life of ~2-3 days, which is long enough that single-weekly dosing is operationally viable. The receptor occupancy curve under 1-2x weekly subq (loading phase); maintenance lower dosing at 2-5 mg per dose explains the typical onset timeline for healthspan and biological-age endpoints.

Home/ Compounds/ TB-500

TB-500

Longevity

Healthspan-relevant evaluation of TB-500 starts with mapping its mechanism to the hallmarks of aging and asking which of the nine hallmarks its primary pharmacology engages. Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool This influences cell migration during repair, angiogenesis, and stem-cell mobilisation. Acts systemically when injected anywhere, unlike many peptides whose effects are local.. The ~2-3 days pharmacokinetic profile, the cycle-based 2-5 mg 1-2x weekly subq (loading phase); maintenance lower dosing pattern, and the longevity-specific stack partners on adjacent hallmarks together produce the framework documented below.

Longevity / Hallmarks of Aging Applications

Cellular ReprogrammingNAD+ MetabolismAutophagy InductionmTOR ModulationTelomere Support

Key Takeaways

Longevity lens: TB-500 maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 2-5 mg 1-2x weekly subq (loading phase); maintenance lower dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. This influences cell migration during repair, angiogenesis, and stem-cell mobilisation. Acts systemically when injected anywhere, unlike many peptides whose effects are local. Hallmarks-of-aging mapping for TB-500: which of the nine hallmarks does this mechanism engage? The subsections below address TB-500's mapping to the hallmark framework, its effects on cellular reprogramming and gene expression, healthspan biomarker movement, and the cycle-based versus continuous dosing question that frames longevity-research protocol design.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after TB-500 cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Cellular reprogramming and gene expression

Where TB-500 has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.

Mapping to the hallmarks of aging

TB-500's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. This influences cell migration during repair, angiogenesis, and stem-cell mobilisation. Acts systemically when injected anywhere, unlike many peptides whose effects are local. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Longevity / Hallmarks of Aging Applications

Senescence Modulation

TB-500's contribution to senescence modulation as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Hallmarks of Aging

Hallmarks of Aging maps to one of the hallmarks of aging and is one of the dimensions on which TB-500 is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Nutrient Sensing

For nutrient sensing as a longevity-relevant endpoint, TB-500 is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

NAD+ Metabolism

TB-500's contribution to nad+ metabolism as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	2-5 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-5 mg	4–6 weeks initial cycle
Longevity focus	SubQ	2-5 mg	1-2x weekly SubQ (loading phase); maintenance lower
Maintenance phase	SubQ	1-5 mg	Ongoing with periodic pauses

Dose timing for TB-500 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

TB-500 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

TB-500 + Epithalon: Identified by Khavinson in St. Pairs naturally with TB-500's mechanism in longevity / hallmarks of aging protocols.
TB-500 + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with TB-500's mechanism in longevity / hallmarks of aging protocols.
TB-500 + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with TB-500's mechanism in longevity / hallmarks of aging protocols.
TB-500 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with TB-500's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Banned (S0) FDA: Unapproved Research: Preclinical + veterinary clinical (equine)

Generally well tolerated. Limited human safety data. Avoid in active cancer.

Lens-specific safety considerations for longevity / hallmarks of aging use of TB-500: Generally well tolerated. Limited human safety data. Avoid in active cancer. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Thymosin β4 and tissue regeneration

PMID 19737543

Supporting

Thymosin β4 — actin sequestration and repair

PMID 22515427

TB-500 vs Related Peptides

Compound	Profile	Onset	Best For
TB-500	Synthetic thymosin β4 fragment	~2-3 days	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

When in life should I start TB-500?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

Cycle-based or continuous dosing for longevity?

Longevity-research convention favours cycle-based and pulsatile interventions over indefinite continuous administration. Hormetic stimulation produces stronger systems-biology effects than sustained agonism for most longevity-relevant endpoints. TB-500 fits this framework with cycle lengths typical for its compound class.

Does TB-500 interact with rapamycin, metformin, or other longevity stacks?

Most peptide compounds are compatible with the standard longevity small-molecule stack (rapamycin, metformin, NAD precursors, senolytics in pulsed protocols). Interactions where present are typically additive rather than competitive. Verify case-specifically with a longevity-informed clinician.

Does TB-500 actually extend lifespan?

Direct lifespan extension in humans cannot be inferred from current data for any peptide compound. The relevant question is whether TB-500 measurably moves healthspan-relevant biomarkers — epigenetic age, telomere length, inflammatory panels, metabolic flexibility — in the direction of younger phenotypes. Some compounds in this class have measurable effects on these markers; the lifespan extrapolation remains inferential.

What are the safety considerations for TB-500?

Generally well tolerated. Limited human safety data. Avoid in active cancer. For healthspan and biological-age use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. TB-500's ~2-3 days pharmacokinetic profile and subq/im administration route influence the side-effect profile in predictable ways.

What is TB-500?

TB-500 (also known as Thymosin β4 fragment / Tβ4(17-23)) is a 17-residue synthetic thymosin β4 fragment with a molecular weight of 888-1717 Da (depending on form) and a plasma half-life of ~2-3 days. Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. This influences cell migration during repair, angiogenesis, and stem-cell mobilisation. Acts systemically when injected anywhere, unlike many peptides whose effects are local. The compound is studied primarily in the longevity / hallmarks of aging domain for the applications outlined above.

Clinical Protocol

Start a TB-500 Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified TB-500 and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 888-1717 Da (depending on form)
Sequence length: 17 aa
Half-life: ~2-3 days
WADA: Banned (S0)
FDA: Unapproved
Research: Preclinical + veterinary clinical (equine)

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for TB-500 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for TB-500

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised